You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: April 2, 2026

Bulk Pharmaceutical API Sources for LO/OVRAL-28


✉ Email this page to a colleague

« Back to Dashboard


Bulk Pharmaceutical API Sources for LO/OVRAL-28

Vendor Vendor Homepage Vendor Sku API Url
J&H Chemical Co.,ltd ⤷  Start Trial JH285923 ⤷  Start Trial
RR Scientific ⤷  Start Trial R207957 ⤷  Start Trial
AKos Consulting & Solutions ⤷  Start Trial AKOS040751734 ⤷  Start Trial
>Vendor >Vendor Homepage >Vendor Sku >API Url

Bulk Active Pharmaceutical Ingredient (API) Sources for LO/OVRAL-28

Last updated: February 21, 2026

LO/OVRAL-28, a combined oral contraceptive, contains two active ingredients: ethinyl estradiol and norgestrel. Its manufacturing relies on high-quality API sourcing from multiple suppliers across regions.

API Composition and Specifications

Active Ingredients:

  • Ethinyl estradiol: Synthetic estrogen
  • Norgestrel: Synthetic progestin

Quality Standards:

  • Complies with USP, EP, or other pharmacopeial standards
  • Typical purity > 99%
  • Heavy metals content below acceptable limits
  • Consistent particle size and dissolution profiles

Regional API Sources

Ethinyl Estradiol

Manufacturers and Regions:

  • China: Top supplier, with over 80% of global production, including Zhejiang Connect Chemicals, Zhejiang Hisun Pharmaceutical, and Shanghai UNICHEM.
  • India: Key providers such as Aurobindo Pharma, Cipla, and Cadila Healthcare.
  • Europe: Smaller volumes, primarily for import substitution, with suppliers like Merck and Teva.

Specifications & Certifications:

  • WHO prequalified APIs available from select Chinese and Indian suppliers.
  • Certifications include ISO 9001, GMP compliance, and batch testing.

Norgestrel

Manufacturers and Regions:

  • India: Major supplier base, including Dr. Reddy’s Laboratories, Sun Pharmaceutical Industries, and Lupin.
  • China: Growing presence; companies like Zhejiang Hisun Pharmaceutical.
  • Europe: Limited, suppliers such as Merck.

Specifications & Certifications:

  • Similar to ethinyl estradiol, with USP or EP standards.
  • Usually supplied as crystalline powder with specified particle sizes.

Major API Suppliers Summary

Region/Country Key Manufacturers Certifications Estimated Market Share Notes
China Zhejiang Connect, Shanghai UNICHEM GMP, ISO, CE marking 60-70% Largest supplier, cost-effective, high volume
India Aurobindo, Cipla, Dr. Reddy’s GMP, WHO prequalification 20-30% Focused on quality, export to mature markets
Europe Merck, Teva EMA-approved, GMP 5-10% Specialty and high-purity APIs

Market Dynamics and Sourcing Risks

  • Cost: Chinese API prices are generally lower owing to manufacturing scale.
  • Quality Control: Indian suppliers maintain strict standards; Chinese suppliers increasingly meet international standards.
  • Regulatory Risks: Export restrictions, quality audits, and compliance issues impact supply chains.

Supply Chain Considerations

  • Lead Times: Generally 3-6 months from purchase order to delivery.
  • Bulk Purchasing: Tends to secure better pricing, but requires quality verification.
  • Geopolitical Factors: Tariffs, trade policies, and sanctions influence supplier selection.

Summary

LO/OVRAL-28 relies predominantly on ethinyl estradiol and norgestrel APIs sourced mainly from China and India. The dominant portion of supply comes from Chinese manufacturers due to cost advantages, with Indian suppliers prioritizing quality compliance. European sources are limited but preferred for high-purity needs.


Key Takeaways

  • The global API sourcing for LO/OVRAL-28 is concentrated in China and India.
  • Chinese suppliers dominate due to scale and pricing but face increasing quality scrutiny.
  • Indian suppliers balance quality with cost advantages.
  • Market risks include regulatory compliance and geopolitical factors.
  • Quality certifications such as GMP and WHO prequalification influence supplier selection.

Frequently Asked Questions

1. What factors influence API pricing for LO/OVRAL-28?
API costs depend on manufacturing scale, purity standards, certification compliance, and regional labor/material costs.

2. How does quality control vary between Chinese and Indian API suppliers?
Chinese suppliers have improved quality assurance processes and comply increasingly with international standards; Indian suppliers maintain high standards, supported by GMP and WHO prequalifications.

3. Are there any approved alternative sources for these APIs?
Limited alternatives exist; high-purity European suppliers are available for specialized needs but at higher costs.

4. What are the main risks associated with sourcing API for LO/OVRAL-28?
Risks include supply shortages, quality inconsistency, regulatory non-compliance, and geopolitical disruptions.

5. How can manufacturers ensure API quality for LO/OVRAL-28?
By engaging suppliers with established GMP, ISO, and WHO certifications, performing routine audits, and conducting batch-specific quality testing.


Sources:
[1] U.S. Pharmacopeia. (2022). USP Monographs on Ethinyl Estradiol and Norgestrel.
[2] GlobalData. (2022). API Market Analysis.
[3] WHO. (2021). Prequalified APIs List.
[4] MarketResearch.com. (2023). API Global Supply Chain Insights.

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.